Literature DB >> 17272316

The role of the outpatient clinic in chemotherapy for patients with unresectable or recurrent gastric cancer.

Kentaro Yamazaki1, Narikazu Boku, Kaoru Shibamoto, Hirofumi Yasui, Akira Fukutomi, Takayuki Yoshino, Shuichi Hironaka, Yusuke Onozawa, Yosuke Otake, Noriaki Hasuike, Hiroyuki Matsubayashi, Tetsuya Inui, Yuichiro Yamaguchi, Hiroyuki Ono.   

Abstract

BACKGROUND: Recently, outpatient chemotherapy centers have become popular in Japan. To clarify the actual conditions of outpatient clinics, we surveyed entire clinical courses of chemotherapy in patients with unresectable or recurrent gastric cancer.
METHODS: From the medical records of 64 patients with unresectable or recurrent gastric cancer with no prior chemotherapy, we obtained data on overall survival, non-hospitalized survival, the number of and reasons for attendance at the outpatient clinic and hospitalization, and medical conditions at discharge.
RESULTS: The median follow-up time was 520 days, the median survival time was 353 days, and the median non-hospitalized survival time was 282 days. Patients attended the outpatient clinic 1917 times in total; 145 (8%) of these were unplanned visits for accidental disease, disease progression, or toxicity. Patients were hospitalized 291 times in total: 110 (38%) of hospitalizations were unplanned or emergencies because of disease progression or toxicity. Patients were discharged 290 times in total; in 56 of these discharges (19%) unresolved medical problems remained, such as toxicity, total parenteral nutrition, or symptoms related to cancer. Three patients (5%) died from treatment-related leucopenia and thrombocytopenia.
CONCLUSIONS: Patients with unresectable and recurrent gastric cancer were treated at outpatient clinics for periods up to 80% longer than the entire clinical course of chemotherapy. However, there were some unplanned or emergency hospitalizations and some patients still experienced medical problems at discharge. The role of the outpatient clinic is very important to chemotherapy for patients with unresectable or recurrent gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17272316     DOI: 10.1093/jjco/hyl145

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  2 in total

1.  Outpatient consolidation treatment with clofarabine in a phase 2 study of older adult patients with previously untreated acute myelogenous leukemia.

Authors:  David Claxton; Harry P Erba; Stefan Faderl; Martha Arellano; Roger M Lyons; Tibor Kovacsovics; Janice Gabrilove; Dirk Huebner; Pritesh J Gandhi; Hagop Kantarjian
Journal:  Leuk Lymphoma       Date:  2011-10-24

2.  Hospital Readmission Following Surgery for Gastric Cancer: Frequency, Timing, Etiologies, and Survival.

Authors:  Shaila J Merchant; Philip H G Ituarte; Audrey Choi; Virginia Sun; Joseph Chao; Byrne Lee; Joseph Kim
Journal:  J Gastrointest Surg       Date:  2015-07-11       Impact factor: 3.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.